“We are very much looking forward to participating in AD/PD, one of the world’s leading scientific meetings in Parkinson’s disease research. It provides us the chance to actively contribute, strengthen our network, and boost confidence in our pipeline,” says Kristina Torfgård, CEO of IRLAB.

The company’s two abstracts are titled:

• Results from REACT-PD - a randomized, placebo-controlled, multi-centre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease. Authors: Joakim Tedroff, Fredrik Hansson, Erik Werner, Olivia Vu Van, Johanna Landström, Nicholas Waters, Clas Sonesson and Susanna Waters.
• Searching for novel CNS therapies in Parkinson’s and Alzheimer’s disease using integrative screening process (ISP): An AI/ML driven phenotypic drug discovery platform. Authors: Susanna Waters, Peder Svensson, Nicholas Waters, Erik Werner, Daniel Andersson, Fredrik Wallner, Joakim Tedroff, Clas Sonesson and Sebastian Oleszko

The abstracts will be presented by Susanna Waters, Director Systems Pharmacology, Sebastian Oleszko, Research Scientist, AI & Computational Biology and Joakim Tedroff, Chief Medical Officer.